Antifibrotic effect of the Chinese herbs Modified Danggui Buxue Decoction on adriamycin-induced nephropathy in rats

Chinese Journal of Integrative Medicine

Volumn 18, Issue 8, 2012, Pages 591-598

  Wei, Ming Gang ^a   Sun, Wei ^b   Xiong, Pei Hua ^a   Shao, Jia De ^b  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b Hospital of Traditional Chinese Medicine of Jiangsu Province   (China)

Author keywords

Adriamycin induced nephropathy rat; Anti fibrosis effect; Chinese herbs; Mechanism

Indexed keywords

ALBUMIN; ANGELICA ROOT; ANTIFIBROTIC AGENT; BENAZEPRIL; CHINESE DRUG; COLLAGEN TYPE 4; DOXORUBICIN; FIBRONECTIN; GELATINASE B; HERBACEOUS AGENT; LIGUSTICUM CHUANXIONG EXTRACT; MODIFIED DANGGUI BUXUE DECOCTION; N ACETYL BETA GLUCOSAMINIDASE; SCLEROPROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTRAGALUS MEMBRANACEUS; BODY WEIGHT; CHINESE HERB; CONTROLLED STUDY; DRUG EFFECT; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENETIC TRANSCRIPTION; IMMUNOHISTOCHEMISTRY; KIDNEY CORTEX; KIDNEY DISEASE; LIPID BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RADIX ANGELICAE SINENSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACETYLGLUCOSAMINIDASE; ANIMALS; BODY WEIGHT; COLLAGEN TYPE IV; DOXORUBICIN; DRUGS, CHINESE HERBAL; FIBRONECTINS; FIBROSIS; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; KIDNEY CORTEX; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MALE; MATRIX METALLOPROTEINASE 9; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SERUM ALBUMIN; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSFORMING GROWTH FACTOR BETA1; TRIGLYCERIDES;

EID: 84867284848     PISSN: 16720415     EISSN: 19930402     Source Type: Journal    
DOI: 10.1007/s11655-011-0816-x     Document Type: Article

References (22)

1. Gabbiani G. The biology of the myofibroblast. Kidney Int 1992;41:530-532.
2. Muchaneta-Kubara EC, el Nahas AM. Myofibroblast phenotypes expression in experimental renal scarring. Nephrol Dial Transplant 1997;12:905-915.
3. Jerums G, Panagiotopoulos S, Tsalamandris C, Allen TJ, Gilbert RE, Comper WD. Why is proteinuria such an important risk factor for progression in clinical trial? Kidney Int 1997;52:S87-S92.
4. Rysz J, Pedzik A, Markuszewski L, Kujawski K, Blaszczak R, Olszewski R. The role of metalloproteinases in kidney pathophysiology. Pol Merkur Lekarski (Polish) 2005;19:812-815.
5. Ahmed AK, Haylor JL, El Nahas AM, Johnson TS. Localization of matrix metalloproteinases and their inhibitors in experimental progressive kidney scarring. Kidney Int 2007;71:755-763.
6. Beaudeux JL, Giral P, Bruckert E, Foglietti MJ, Chapman MJ. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med 2004;42:121-131.
7. Liu S, Li Y, Zhao H, Chen D, Huang Q, Wang S, et al, Huang H. Increase in extracellular cross-linking by tissue transglutaminase and reduction in expression of MMP-9 contribute differentially to focal segmental glomerulosclerosis in rats. Mol Cell Biochem 2006;284:9-17.
8. Wei MG, Xiong PH, Zhang L, Chen AP. The protective effect of Chinese medicine on IgA nephritis-induced renal tubule lesion. J Tradit Chin Med (Chin) 2006;47:839-840.
9. Bertani T, Poggi A, Pozzoni R, Delaini F, Sacchi G, Thoua Y, et al. Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events. Lab Invest 1982;46:16-23.
10. Saad SY, Najjar TA, Al-Rikabi AC. The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. Pharmacol Res 2001;43:211-218.
11. Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J Am Soc Nephrol 2006;17:2974-2984.
12. Dance N, Price RG, Cattell WR, Lansdell J, Richards B. The excretion of N-acetyl-beta-glucosaminidase and beta-galactosidase by patients with renal disease. Clin Chim Acta 1970;27:87-92.
13. Oseto S, Moriyama T, Kawada N, Nagatoya K, Takeji M, Ando A, et al. Therapeutic effect of all-transretinoic acid on rats with anti-GBM antibody glomerulonephritis. Kidney Int 2003;64:1241-1252.
14. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331:1286-1292.
15. Varga J, Rosenbloom J, Jimenez SA. Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J 1987;247:597-604.
16. McAnulty RJ, Campa JS, Cambrey AD, Laurent GJ. The effect of transforming growth factor beta on rates of procollagen synthesis and degradation in vitro. Biochim Biophys Acta 1991;1091:231-235.
17. Van Obberghen-Schilling E, Roche NS, Flanders KC, Sporn MB, Roberts AB. Transforming growth factor beta 1 positively regulates its own expression in normal and transformed cells. J Biol Chem 1988;263:7741-7746.
18. Fu XY, Park WC, Heineche JW. Activation and silencing of matrix metalloproteinases. Semin Cell Dev Biol 2008;19:2-13.
19. Steinmann-Niggli K, Ziswiler R, Küng M, Marti HP. Inhibition of matrix metalloproteinases attenuates anti-Thyl.1 nephritis. J Am Soc Nephrol 1998;9:397-407.
20. McMillan JI, Riordan JW, Couser WG, Pollock AS, Lovett DH. Characterization of glomerular epithelial cell metalloproteinaseas matrix metalloproteinase-9 with chanced expression in a model of membranous nephropathy. J Clin Invest 1996;97:1094-1101.
21. Wagner J, Dechow C, Morath C, Lehrke I, Amann K, Waldherr R, et al. Retinoic acid reduces glomerular injury in a rat model of glomerular damage. J Am Soc Nephrol 2000;11:1479-1487.
22. Sun SZ, Wang Y, Li Q, Tian YJ, Liu MH, Yu YH. Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats. Chin Med J 2006;119:814-821.